Poplack S P, Tosteson A N, Grove M R, Wells W A, Carney P A
Departments of Radiology, Dartmouth-Hitchcock Medical Center, 1 Medical Center Dr, HB 7999, Lebanon, NH 03756, USA.
Radiology. 2000 Dec;217(3):832-40. doi: 10.1148/radiology.217.3.r00dc33832.
To describe measures of mammography performance in a geographically defined population and evaluate the interpreter's use of the Breast Imaging Reporting and Data System (BI-RADS).
Mammographic data from 47,651 screening and 6,152 diagnostic examinations from November 1, 1996, to October 31, 1997, were linked to 1,572 pathologic results. Mammographic outcomes were based on BI-RADS assessments and recommendations reported by the interpreting radiologist. The consistency of BI-RADS recommendations was evaluated.
Screening mammography had a sensitivity of 72.4% (95% CI: 66.4%, 78.4%), specificity of 97.3% (95% CI: 97.25%, 97.4%), and positive predictive value of 10.6% (95% CI: 9.1%, 12.2%). Diagnostic mammography had higher sensitivity, 78.1% (95% CI: 71.9%, 84.3%); lower specificity, 89.3% (95% CI: 88.5%, 90.1%); and better positive predictive value, 17.1% (95% CI: 14.5%, 19.8%). The cancer detection rate with screening mammography was 3.3 per 1,000 women, with a biopsy yield of 22.4%, whereas the interval cancer rate was 1. 2 per 1,000. Nearly 80% of screening-detected invasive malignancies were node negative. The recall rate for screening mammography was 8. 3%. Ultrasonography was used in 3.5% of screening and 17.5% of diagnostic examinations. BI-RADS recommendations were generally consistent, except for probably benign assessments.
The sensitivity of screening mammography in this population-based sample is lower than expected, although other performance indicators are commendable. BI-RADS "probably benign" assessments are commonly misused.
描述在一个地理定义明确的人群中乳腺钼靶检查的性能指标,并评估解读医生对乳腺影像报告和数据系统(BI-RADS)的使用情况。
将1996年11月1日至1997年10月31日期间47651例筛查性和6152例诊断性乳腺钼靶检查数据与1572例病理结果相关联。乳腺钼靶检查结果基于解读放射科医生报告的BI-RADS评估和建议。评估了BI-RADS建议的一致性。
筛查性乳腺钼靶检查的敏感性为72.4%(95%CI:66.4%,78.4%),特异性为97.3%(95%CI:97.25%,97.4%),阳性预测值为10.6%(95%CI:9.1%,12.2%)。诊断性乳腺钼靶检查具有更高的敏感性,为78.1%(95%CI:71.9%,84.3%);更低的特异性,为89.3%(95%CI:88.5%,90.1%);以及更好的阳性预测值,为17.1%(95%CI:14.5%,19.8%)。筛查性乳腺钼靶检查的癌症检出率为每1000名女性中有3.3例,活检率为22.4%,而间期癌症发生率为每1000名中有1.2例。筛查发现的浸润性恶性肿瘤中近80%为无淋巴结转移。筛查性乳腺钼靶检查的召回率为8.3%。超声检查在3.5%的筛查检查和17.5%的诊断检查中使用。除了可能为良性的评估外,BI-RADS建议总体上是一致的。
在这个基于人群的样本中,筛查性乳腺钼靶检查的敏感性低于预期,尽管其他性能指标值得称赞。BI-RADS“可能为良性”的评估经常被误用。